Alnylam Pharmaceuticals, Inc.
NASDAQ: ALNY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,230
- Headquarters
- Cambridge, United States
- IPO year
- 2004
- Market cap
- $37.1B
- Website
- https://www.alnylam.com
Loading ALNY…
Loading profile data…Frequently asked questions about ALNY
What does Alnylam Pharmaceuticals, Inc. (ALNY) do?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited gen...
Where does ALNY trade?
Alnylam Pharmaceuticals, Inc. (ALNY) trades on the NASDAQ Global Select.
What sector is ALNY in?
Alnylam Pharmaceuticals, Inc. (ALNY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alnylam Pharmaceuticals, Inc.?
Yvonne L. Greenstreet is the chief executive officer of Alnylam Pharmaceuticals, Inc. (ALNY).
Where is Alnylam Pharmaceuticals, Inc. headquartered?
Alnylam Pharmaceuticals, Inc. is headquartered in United States.
Does ALNY pay a dividend?
Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALNY go public?
Alnylam Pharmaceuticals, Inc. (ALNY) completed its initial public offering in 2004.